We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.5B
AUM Growth
+$439M
Cap. Flow
-$3.35M
Cap. Flow %
-0.06%
Top 10 Hldgs %
41.65%
Holding
136
New
22
Increased
21
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$87.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$46.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.6M
4
AMGN icon
Amgen
AMGN
+$38.4M
5
UNH icon
UnitedHealth
UNH
+$37.9M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$74.9M
2
THC icon
Tenet Healthcare
THC
+$59.2M
3
VRNA
Verona Pharma
VRNA
+$41.4M
4
GERN icon
Geron
GERN
+$40.6M
5
PCVX icon
Vaxcyte
PCVX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Miscellaneous 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCPH
51
DELISTED
scPharmaceuticals
SCPH
$27.6M 0.5%
6,059,528
+500,000
+9% +$2.42M
VIR icon
52
Vir Biotechnology
VIR
$1.77B
$26.8M 0.49%
3,573,000
+1,252,898
+54% +$10.9M
PHAT icon
53
Phathom Pharmaceuticals
PHAT
$671M
$26.2M 0.48%
+1,449,073
New +$20.3M
CGON icon
54
CG Oncology
CGON
$6.48B
$26.1M 0.47%
+691,114
New +$24.2M
DYN icon
55
Dyne Therapeutics
DYN
$3.37B
$25.4M 0.46%
708,400
– –
CCCC icon
56
C4 Therapeutics
CCCC
$423M
$25M 0.45%
4,377,900
+2,864,842
+189% +$17.2M
MLYS icon
57
Mineralys Therapeutics
MLYS
$2.51B
$24.3M 0.44%
2,002,939
-18,485
-0.9% -$224K
NPCE icon
58
Neuropace
NPCE
$489M
$23.7M 0.43%
3,406,335
– –
IMTX icon
59
Immatics
IMTX
$1.31B
$22.9M 0.42%
2,006,381
– –
RYTM icon
60
Rhythm Pharmaceuticals
RYTM
$6.71B
$22.8M 0.41%
435,900
-268,942
-38% -$12.9M
PRLD icon
61
Prelude Therapeutics
PRLD
$356M
$22.6M 0.41%
10,909,256
– –
APGE
62
DELISTED
Apogee Therapeutics
APGE
$22.3M 0.4%
379,130
– –
NMRA icon
63
Neumora Therapeutics
NMRA
$167M
$19.8M 0.36%
1,500,000
– –
SLRN
64
DELISTED
ACELYRIN
SLRN
$19.7M 0.36%
4,001,711
– –
CRBP icon
65
Corbus Pharmaceuticals
CRBP
$129M
$18.8M 0.34%
+912,552
New +$46.7M
TYRA icon
66
Tyra Biosciences
TYRA
$1.52B
$18.1M 0.33%
768,638
– –
CGEM icon
67
Cullinan Oncology
CGEM
$1.31B
$17.9M 0.33%
1,070,055
-77,600
-7% -$1.38M
LXRX icon
68
Lexicon Pharmaceuticals
LXRX
$850M
$17.3M 0.31%
11,024,000
+5,177,900
+89% +$9.22M
GPCR icon
69
Structure Therapeutics
GPCR
$2.76B
$16.8M 0.31%
383,705
+258,705
+207% +$10M
ACET icon
70
Adicet Bio
ACET
$76.1M
$16.5M 0.3%
715,446
– –
MEDP icon
71
Medpace
MEDP
$17.2B
$15M 0.27%
+44,900
New +$17.1M
ADCT icon
72
ADC Therapeutics
ADCT
$131M
$14.3M 0.26%
4,533,801
+216,977
+5% +$684K
GILD icon
73
Gilead Sciences
GILD
$181B
$12.7M 0.23%
+151,700
New +$11.6M
BNTX icon
74
BioNTech
BNTX
$24.5B
$12.2M 0.22%
+103,000
New +$9.47M
ACAD icon
75
Acadia Pharmaceuticals
ACAD
$4.63B
$11.8M 0.21%
+764,600
New +$12.8M
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2024 Portfolio in Review

As of Q3 2024, OrbiMed held 136 positions worth $5.5B, up 8.7% from $5.06B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q3 2024 filing shows 22 new, 21 increased, 31 reduced and 18 closed positions. Its largest new stake was MBX Biosciences: 3,812,215 shares worth $99M. The largest sale was Janux Therapeutics, an estimated $74.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q3 2024 buy was MBX Biosciences: 3,812,215 shares worth $99M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2024, an estimated $42.6M increase.
  • OrbiMed's biggest Q3 2024 reduction was Janux Therapeutics, cutting an estimated $74.9M.
  • OrbiMed fully exited Verona Pharma in Q3 2024, selling an estimated $41.4M.
  • OrbiMed's ten largest holdings make up 42% of its $5.5B portfolio in Q3 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q3 2024.
  • OrbiMed's portfolio value rose 8.7% quarter-over-quarter to $5.5B.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.